Please review our Corporate Presentation here – BeyondSpring Corporate Presentation November 13, 2026
Nov 13, 2026
FDA Fast Track Designation for Plinabulin plus docetaxel marks key regulatory milestone in DUBLIN-4 study population of Post-ICI Non-Squamous NSCLC…
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in…
Sep 29, 2026
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint…
Aug 14, 2026
Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and…
Jun 04, 2026
2026 ASCO
Jun 03, 2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC…
Jun 02, 2026
Florham Park, NJ, May 18, 2026 — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative…
May 18, 2026
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer…
May 13, 2026
Tempor eros commodo sit amet rhoncus pharetra. Diam gravida libero egestas diam rhoncus penatibus amet vitae.
Email us at
Call us at
Office location